Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rezolute, Inc.

4.20
-0.2000-4.55%
Post-market: 4.370.1735+4.13%19:58 EDT
Volume:345.00K
Turnover:1.47M
Market Cap:359.18M
PE:-3.77
High:4.39
Open:4.33
Low:4.20
Close:4.40
Loading ...

Rezolute Inc. Announces $4.2 Million Private Placement with Key Investors

Reuters
·
Yesterday

BTIG Reaffirms Their Buy Rating on Rezolute (RZLT)

TIPRANKS
·
29 May

BRIEF-Rezolute Announces Completion Of Enrollment In The Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism

Reuters
·
28 May

Rezolute complete enrollment in Phase 3 sunRIZE study of ersodetug

TIPRANKS
·
28 May

Rezolute Inc - Topline Data Anticipated in December 2025

THOMSON REUTERS
·
28 May

Rezolute Announces Completion of Enrollment in the Phase 3 Sunrize Study of Ersodetug in Patients With Congenital Hyperinsulinism

THOMSON REUTERS
·
28 May

Rezolute Inc - Anticipates Bla Submission for Ersodetug in 2026

THOMSON REUTERS
·
28 May

U.S. RESEARCH ROUNDUP-Fair Issac, First Solar, UnitedHealth

Reuters
·
14 May

Rezolute Inc : Jefferies Cuts Target Price to $13 From $16

THOMSON REUTERS
·
14 May

Rezolute Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Rezolute Q3 EPS $(0.27) Misses $(0.23) Estimate

Benzinga
·
14 May

BRIEF-Rezolute Q3 EPS USD -0.27

Reuters
·
14 May

Press Release: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Dow Jones
·
14 May

Rezolute Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
09 May

Sector Update: Health Care Stocks Lower Monday Afternoon

MT Newswires Live
·
06 May

Rezolute Gets US FDA Breakthrough Therapy Designation for Hypoglycemia Treatment

MT Newswires Live
·
05 May

Analysts Are Bullish on These Healthcare Stocks: Capricor Therapeutics (CAPR), Rezolute (RZLT)

TIPRANKS
·
05 May

Rezolute Receives Breakthrough Therapy Designation From FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

THOMSON REUTERS
·
05 May

Rezolute Inc - Registrational Study of Ersodetug to Start Mid-2025

THOMSON REUTERS
·
05 May

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

GlobeNewswire
·
05 May